Dear all,
<br>
<br>Call for papers for a panel on "Responsible innovation in the emerging
<br>synthetic biology industry". This panel is part of a series of RRI events
<br>that will be held alongside the UK Synthetic Biology conference in Bristol,
<br>19-20 November (organised by BrisSynBio).
<br>
<br>
<br>
<br>Responsible innovation in the emerging synthetic biology industry: challenges,
<br>possibilities, implications
<br>
<br>Organizers: Achim Rosemann, Sally Atkinson and Susan Molyneux-Hodgson
<br>(University of Exeter).
<br>
<br>
<br>
<br>RRI frameworks encourage broad, early-stage public engagement and continuous
<br>collaboration between societal actors during the whole of the research and
<br>innovation process. While the origins of RRI lie primarily in academia and the
<br>publicly funded research sector, in recent years the concept has started to
<br>play an increasingly important role in industry innovation. However, as
<br>various commentators have pointed out, there are significant tensions between
<br>public sector RRI and the characteristics and practices of industry innovation
<br>(Dreyer et al. 2017; Lubberink et al. 2017; Stahl 2018).
<br>
<br>This panel seeks to explore the challenges, possibilities and implications of
<br>the adoption of RRI ideas, concepts and tools in emerging synthetic biology
<br>industries. Corporations are expected to play a leading role in the
<br>commercialization of synthetic biology over the next years, but how feasible
<br>are existing RRI concepts for industrial biotechnology companies that use
<br>synthetic biology techniques? To what extent and how do (or will) companies
<br>engage with RRI? And how do the meanings, practices and aims of RRI change in
<br>the context of industrial commercialization?
<br>
<br>More specifically, the panel aims to generate insights into:
<br>
<br> * the emerging concepts, discourses and meanings of RRI in the context of
<br>the "industrialization" of synthetic biology
<br> * the ways in which RRI ideas are translated into actual practices in
<br>biotech corporations
<br> * the hurdles and challenges for the adoption and implementation of RRI
<br>ideas in industrial biotechnology innovation
<br> * the tensions between public sector RRI and the characteristics and
<br>requirements of industry innovation
<br> * the (financial, organizational, discursive, etc) implications of the
<br>adoption of RRI ideas in industrial biotechnology, and the ways in which the
<br>adoption of RRI in corporations changes actual innovation and
<br>commercialisation practices
<br>Process and Deadline:
<br>
<br>If you would like to participate in this panel, please send your abstract to:
<br>a.rosemann@exeter.ac.uk by 18 September 2018.
<br>Abstracts should be 250 words.
<br>
<br>Many thanks,
<br>Sally
<br>Sally Atkinson
<br>Research Associate (Anthropology)
<br>University of Exeter
<br>Telephone: 01392 72 5133
<br>www.exeter.ac.uk
<br>Byrne House, St German's Road , Exeter, Devon, EX4 4PJ
<br>[http://www.exeter.ac.uk/codebox/email-sig/staff-sig.gif]
<br>This email and any attachment may contain information that is confidential,
<br>privileged, or subject to copyright, and which may be exempt from disclosure
<br>under applicable legislation. It is intended for the addressee only. If you
<br>received this message in error, please let me know and delete the email and
<br>any attachments immediately. The University will not accept responsibility for
<br>the accuracy/completeness of this email and its attachments.
<br>_______________________________________________
<br>EASST's Eurograd mailing list
<br>Eurograd (at) lists.easst.net
<br>Unsubscribe or edit subscription options: http://lists.easst.net/listinfo.cgi/eurograd-easst.net
<br>
<br>Meet us via https://twitter.com/STSeasst
<br>
<br>Report abuses of this list to Eurograd-owner@lists.easst.net
view formatted text
